Search

654 Result(s)
Sort by

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
1885-1948: Innovative beginnings

1885-1948: Innovative beginnings

The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
Big hearts united to help animals in Ukraine

Big hearts united to help animals in Ukraine

Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.
Collaboration Driving Innovation

Collaboration Driving Innovation

In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.